Our Mission

We build platforms for


The Access to Advanced Health Institute Announces $9.9M Award to Develop a Nasal Spray Influenza RNA Vaccine Through Phase 1 Clinical Trials

AAHI recently awarded a project agreement through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype itnranasal bivalent influenza RNA vaccine candidate that targets both pandemic A(H5N1) and A(H7N9) influenza virus pathogens.

Learn More

The Challenges of Vaccine Transport and Storage

The COVID-19 pandemic brought global attention to the process of developing a new vaccine. Emily Voigt, PhD, Principal Scientist and AAHI’s RNA Platform lead tells Technology Networks about AAHI’s approach to developing simpler, potent, and temperature stable RNA vacicne technology.

Learn More

Experimental COVID-19 Vaccine Offers Long-Term Protection Against Severe Disease

Adding AAHI’s 3M-052-SE adjuvant formulation to a traditional protein vaccine allowed for broad protection against SARS-CoV-2 and its variants lasting at least a year, potentially overcoming a key limitation of current RNA vaccines.

Learn More

AAHI Develops Longer Lasting and Broadly Protective SARS-CoV-2 RNA Vaccine Candidate that is Stable at Room Temperature

AAHI’s new self-amplifying RNA vaccine candidate against COVID-19 induces strong immune responses against multiple variants of SARS-CoV-2 and can easily be freeze-dried for long-term room-temperature or refrigerated stability (10+ months).

Learn More

We Discover

AAHI leverages its RNA and adjuvant formulations expertise to pioneer the development of platforms for next generation vaccines and immunotherapies.

We Develop

Our in-house manufacturing, formulation, and product development services enable development of powerful prophylactic and therapeutic solutions to address real-world needs.

We Deploy

Our platform technology facilitates rapid vaccine and immunotherapy development and distribution, to make life-enhancing products equitably accessible around the world.

Our Formulations

Next Generation Solutions

Our expertise in RNA vaccines and adjuvant formulations has set the stage for revolutionary development and improvement of potent, broad, and durable vaccines that are commercially scalable and accessible across diverse geographic, cultural, and economic regions.


Who Is AAHI?

AAHI is focused on solving fundamental scientific challenges that impede the ability of the biomedical community to deliver on our shared goal – protecting and improving people’s health around the world.


AAHI Is All About Collaboration

Our commitment to global equity permeates our efforts to forge collaborations and partnerships to make immunologic innovations equitably accessible to the people who most need them.


Sign up to stay in touch!

Get the latest news and updates in your inbox every month and learn more about how our scientists are developing equitably accessible vaccines and therapeutics for people who most need them.